Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin

Zhang,Jinli; Xiong,Xifeng; Hua,Xing; Cao,Wenjuan; Qin,Shengnan; Dai,Libing; Liang,Peihong; Zhang,Huiling; Liu,Zhihe

doi:10.3892/ol.2017.6978

Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin

Authors:
- Jinli Zhang
- Xifeng Xiong
- Xing Hua
- Wenjuan Cao
- Shengnan Qin
- Libing Dai
- Peihong Liang
- Huiling Zhang
- Zhihe Liu
View Affiliations

Affiliations: Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, Guangdong 510220, P.R. China, Department of Pathology, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, Guangdong 510220, P.R. China, Department of Pharmacology, College of Pharmaceutical Science, Soochow University, Suzhou, Jiangsu 215123, P.R. China
Published online on: September 15, 2017 https://doi.org/10.3892/ol.2017.6978
Pages: 5819-5824
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial ovarian cancer (EOC) affects almost 25,000 women annually and is the fifth most common malignancy in women in North America. A combination of surgery and cytotoxic chemotherapy may produce a favorable clinical response. The platinum‑paclitaxel combination regimen is the chemotherapy gold‑standard for advanced ovarian cancer, and carboplatin is one of the agents in this combination therapy. However, the majority of patients eventually experience a relapse due to the development of platinum resistance. FUSE binding protein 1 (FBP1) has been identified as an anti‑apoptotic and pro‑proliferative oncoprotein that is overexpressed in hepatocellular carcinoma. Its high expression is also associated with carboplatin resistance. In the present study, it was identified that the expression of FBP1 was significantly higher in EOC tissues than in normal epithelial ovarian or in epithelial ovarian adenoma tissue. FBP1 expression was significantly correlated with the grade of epithelial ovarian cancer. Carboplatin inhibited the expression of FBP1 in epithelial ovarian cancer cells and the knockdown of FBP1 enhanced the inhibition of cell viability and migration by carboplatin. In addition to FBP1, carboplatin also inhibited the expression of β‑catenin and matrix metalloproteinase (MMP)‑9. Furthermore, the expression of β‑catenin and MMP‑9 were lower in FBP1 knockdown cells compared with control EOC cells. FBP1 may thus serve a role in the regulation of the expression of β‑catenin and MMP‑9; the inhibition of β‑catenin and MMP‑9 by carboplatin may be mediated through the inhibition of FBP1. The inhibition of FBP1 expression by carboplatin may be a mechanism in the treatment of EOC by carboplatin.

View Figures

View References

1	A JY, . Wang GJ, Sun JG, Gu YC, Wu MS and Liu JH: Identification of phase I and phase II metabolites of Guanfu base A hydrochloride in human urine. Eur J Drug Metab Pharmacokinet. 28:265–272. 2003. View Article : Google Scholar : PubMed/NCBI
2	Berkenblit A and Cannistra SA: Advances in the management of epithelial ovarian cancer. J Reprod Med. 50:426–438. 2005.PubMed/NCBI
3	Salom E, Almeida Z and Mirhashemi R: Management of recurrent ovarian cancer: Evidence-based decisions. Curr Opin Oncol. 14:519–527. 2002. View Article : Google Scholar : PubMed/NCBI
4	Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R: Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
6	du Bois A, Neijt JP and Thigpen JT: First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol. 10 Suppl 1:S35–S41. 1999. View Article : Google Scholar : PubMed/NCBI
7	Biagi JJ and Eisenhauer EA: Systemic treatment policies in ovarian cancer: The next 10 years. Int J Gynecol Cancer. 13 Suppl 2:S231–S240. 2003. View Article : Google Scholar
8	Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B and van Houwelingen HC: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 18:3084–3092. 2000. View Article : Google Scholar : PubMed/NCBI
9	Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
10	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
11	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
12	Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar : PubMed/NCBI
13	Gore ME, Fryatt I, Wiltshaw E and Dawson T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:207–211. 1990. View Article : Google Scholar : PubMed/NCBI
14	Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, et al: Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. Hepatology. 50:1130–1139. 2009. View Article : Google Scholar : PubMed/NCBI
15	Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL and Zörnig M: Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology. 50:1121–1129. 2009. View Article : Google Scholar : PubMed/NCBI
16	Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I and Győrffy B: MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer. 14:8372014. View Article : Google Scholar : PubMed/NCBI
17	Chung HJ and Levens D: c-myc expression: keep the noise down! Mol Cells. 20:157–166. 2005.PubMed/NCBI
18	Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M and Levens D: A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev. 8:465–480. 1994. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Chung HJ, Vogt M, Jin Y, Malide D, He L, Dundr M and Levens D: JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J. 30:846–858. 2011. View Article : Google Scholar : PubMed/NCBI
20	Rabenhorst U, Thalheimer FB, Gerlach K, Kijonka M, Böhm S, Krause DS, Vauti F, Arnold HH, Schroeder T, Schnütgen F, et al: Single-Stranded DNA-Binding Transcriptional Regulator FUBP1 Is Essential for Fetal and Adult Hematopoietic Stem Cell Self-Renewal. Cell Rep. 11:1847–1855. 2015. View Article : Google Scholar : PubMed/NCBI
21	Dixit U, Liu Z, Pandey AK, Kothari R and Pandey VN: Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53. BMC Cancer. 14:9252014. View Article : Google Scholar : PubMed/NCBI
22	Dixit U, Pandey AK, Liu Z, Kumar S, Neiditch MB, Klein KM and Pandey VN: FUSE Binding Protein 1 facilitates persistent hepatitis C virus replication in hepatoma cells by regulating tumor suppressor p53. J Virol. 89:7905–7921. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, et al: A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat. 147:579–588. 2014. View Article : Google Scholar : PubMed/NCBI
24	Rask K, Nilsson A, Brännström M, Carlsson P, Hellberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling pathway in ovarian epithelial tumours: Increased expression of beta-catenin and GSK3beta. Br J Cancer. 89:1298–1304. 2003. View Article : Google Scholar : PubMed/NCBI
25	Barghout SH, Zepeda N, Xu Z, Steed H, Lee CH and Fu Y: Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells. Biochem Biophys Res Commun. 468:173–178. 2015. View Article : Google Scholar : PubMed/NCBI
26	Murphy G and Nagase H: Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J. 278:2–15. 2011. View Article : Google Scholar : PubMed/NCBI
27	Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, Prusa R and Kizek R: Matrix metalloproteinases. Curr Med Chem. 17:3751–3768. 2010. View Article : Google Scholar : PubMed/NCBI
28	Butler GS and Overall CM: Updated biological roles for matrix metalloproteinases and new ‘intracellular’ substrates revealed by degradomics. Biochemistry. 48:10830–10845. 2009. View Article : Google Scholar : PubMed/NCBI
29	Rodríguez D, Morrison CJ and Overall CM: Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 1803:39–54. 2010. View Article : Google Scholar : PubMed/NCBI
30	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
31	Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L and Winberg JO: Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 278:28–45. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhang J and Chen QM: Far upstream element binding protein 1: A commander of transcription, translation and beyond. Oncogene. 32:2907–2916. 2013. View Article : Google Scholar : PubMed/NCBI
33	Wang YY, Gu XL, Wang C, Wang H, Ni QC, Zhang CH, Yu XF, Yang LY, He ZX, Mao GX and Yang SY: The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines. Tumour Biol. 37:9755–9769. 2016. View Article : Google Scholar : PubMed/NCBI